BIIB’s Lecanemab: Enthusiasm vs Medicare Coverage Realities

This week’s enthusiasm surrounding preliminary data issued by BIIB/Eisai on the pivotal Phase 3 trial of lecanemab may not be met with the same level of excitement by U.S. government regulators, in our view.  In a note to subscribers this morning, Nephron’s Sasha Simpson highlighted key considerations for the pathway to Medicare coverage and why we think the Clarity AD trial alone is unlikely to cause CMS to reopen the existing national coverage policy Alzheimer’s drugs.  For more information on this report and Nephron Research please email